Schmitt-Rau, K <br/><br/>
Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis.  [electronic resource] 

 -  Dermatology (Basel, Switzerland)  2010 
 - 236-42 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1421-9832 
<br/><br/><label>Standard No.: </label>10.1159/000320111  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Anti-Inflammatory Agents--economics<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Cost-Benefit Analysis<br/>Etanercept<br/>Germany<br/>Health Care Costs<br/>Humans<br/>Immunoglobulin G--economics<br/>Immunologic Factors--economics<br/>Infliximab<br/>Psoriasis--drug therapy<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Remission Induction<br/>Ustekinumab